Interplay of drug metabolizing CYP450 enzymes and ABC transporters in the blood-brain barrier

Current Drug Metabolism

Volumn 12, Issue 8, 2011, Pages 732-741

  Declèves, Xavier ^a,b   Jacob, Aude ^a,b   Yousif, Salah ^a,b   Shawahna, Ramzi ^a,b   Potin, Sophie ^a,b   Scherrmann, Jean Michel ^a,b  

^a CNRS   (France)

^b INSERM   (France)

Author keywords

ATP binding cassette transporters; Blood brain barrier; Cytochromes P450; Expression; Interplay; Regulation

Indexed keywords

ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450; CYTOCHROME P450 1B1; CYTOCHROME P450 2U1; DASATINIB; ERLOTINIB; FLAVOPIRIDOL; GEFITINIB; GLYCOPROTEIN P; IMATINIB; LAPATINIB; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 4; PRAZOSIN; TOPOTECAN; UNCLASSIFIED DRUG;

BLOOD BRAIN BARRIER; HUMAN; MICROVASCULAR ENDOTHELIAL CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

EID: 80053555632     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920011798357024     Document Type: Review

References (107)

1. Kamiie, J.; Ohtsuki, S.; Iwase, R.; Ohmine, K.; Katsukura, Y.;Yanai, K.; Sekine, Y.; Uchida, Y.; Ito, S.; Terasaki, T. Quantitativeatlas of membrane transporter proteins: development and applicationof a highly sensitive simultaneous LC/MS/MS method combinedwith novel in-silico peptide selection criteria. Pharm. Res.,2008, 25(6), 1469-1483.
2. Dauchy, S.; Dutheil, F.; Weaver, R. J.; Chassoux, F.; Daumas-Duport, C.; Couraud, P. O.; Scherrmann, J. M.; De Waziers, I.; Declèves,X. ABC transporters, cytochromes P450 and their maintranscription factors: expression at the human blood-brain barrier.J. Neurochem., 2008, 107(6), 1518-1528.
3. Benet, L. Z. The drug transporter-metabolism alliance: uncoveringand defining the interplay. Mol. Pharm., 2009, 6(6), 1631-1643.
4. Benet, L. Z.; Cummins, C. L.; Wu, C. Y. Transporter-enzymeinteractions: implications for predicting drug-drug interactionsfrom in vitro data. Curr. Drug Metab., 2003, 4(5), 393-398. (Pubitemid 37279364)
5. Abbott, N. J.; Patabendige, A. A.; Dolman, D. E.; Yusof, S. R.;Begley, D. J. Structure and function of the blood-brain barrier.Neurobiol. Dis., 2010, 37(1), 13-25.
6. Scherrmann, J. M. Expression and function of multidrug resistancetransporters at the blood-brain barriers. Expert Opin. Drug Metab.Toxicol., 2005, 1(2), 233-246.
7. Begley, D. J. ABC transporters and the blood-brain barrier. Curr.Pharm. Des., 2004, 10(12), 1295-1312. (Pubitemid 38559749)
8. Dean, M.; Rzhetsky, A.; Allikmets, R. The human ATP-bindingcassette (ABC) transporter superfamily. Genome Res., 2001, 11(7),1156-1166. (Pubitemid 32677289)
9. Thiebaut, F.; Tsuruo, T.; Hamada, H.; Gottesman, M. M.; Pastan,I.; Willingham, M. C. Cellular localization of the multidrugresistancegene product P-glycoprotein in normal human tissues.Proc. Natl. Acad. Sci. U S A, 1987, 84(21), 7735-7738.
10. Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug resistance incancer: role of ATP-dependent transporters. Nat. Rev. Cancer,2002, 2(1), 48-58. (Pubitemid 37328807)
11. Volk, H.; Potschka, H.; Loscher, W. Immunohistochemical localizationof P-glycoprotein in rat brain and detection of its increasedexpression by seizures are sensitive to fixation and staining variables.J. Histochem. Cytochem., 2005, 53(4), 517-531. (Pubitemid 40463506)
12. Urquhart, B. L.; Kim, R. B. Blood-brain barrier transporters andresponse to CNS-active drugs. Eur. J. Clin. Pharmacol., 2009,65(11), 1063-1070.
13. Miller, D. S.; Bauer, B.; Hartz, A. M. Modulation of P-glycoproteinat the blood-brain barrier: opportunities to improve central nervoussystem pharmacotherapy. Pharmacol. Rev., 2008, 60(2), 196-209. (Pubitemid 351962009)
14. Juliano, R. L.; Ling, V. A surface glycoprotein modulating drugpermeability in Chinese hamster ovary cell mutants. Biochim. Biophys.Acta, 1976, 455(1), 152-162.
15. Cordon-Cardo, C.; O'Brien, J. P.; Casals, D.; Rittman-Grauer, L.;Biedler, J. L.; Melamed, M. R.; Bertino, J. R. Multidrug-resistancegene (P-glycoprotein) is expressed by endothelial cells at bloodbrainbarrier sites. Proc. Natl. Acad. Sci. U S A, 1989, 86(2), 695-698. (Pubitemid 19037807)
16. Kwan, P.; Sills, G. J.; Butler, E.; Gant, T. W.; Brodie, M. J. Differentialexpression of multidrug resistance genes in naive rat brain.Neurosci. Lett., 2003, 339(1), 33-36. (Pubitemid 36263215)
17. Regina, A.; Demeule, M.; Laplante, A.; Jodoin, J.; Dagenais, C.;Berthelet, F.; Moghrabi, A.; Beliveau, R. Multidrug resistance inbrain tumors: roles of the blood-brain barrier. Cancer MetastasisRev., 2001, 20(1-2), 13-25. (Pubitemid 34074674)
18. Schinkel, A. H.; Smit, J. J.; van Tellingen, O.; Beijnen, J. H.; Wagenaar,E.; van Deemter, L.; Mol, C. A.; van der Valk, M. A.; Robanus-Maandag, E. C.; te Riele, H. P.; et al. Disruption of themouse mdr1a P-glycoprotein gene leads to a deficiency in theblood-brain barrier and to increased sensitivity to drugs. Cell, 1994,77(4), 491-502. (Pubitemid 24153990)
19. Cisternino, S.; Rousselle, C.; Dagenais, C.; Scherrmann, J. M.Screening of multidrug-resistance sensitive drugs by in situ brainperfusion in P-glycoprotein-deficient mice. Pharm. Res., 2001,18(2), 183-190. (Pubitemid 32592598)
20. Fricker, G.; Nobmann, S.; Miller, D. S. Permeability of porcineblood brain barrier to somatostatin analogues. Br. J. Pharmacol.,2002, 135(5), 1308-1314. (Pubitemid 34259133)
21. Jette, L.; Tetu, B.; Beliveau, R. High levels of P-glycoprotein detectedin isolated brain capillaries. Biochim. Biophys. Acta, 1993,1150(2), 147-154. (Pubitemid 23246705)
22. Miller, D. S.; Graeff, C.; Droulle, L.; Fricker, S.; Fricker, G. Xenobioticefflux pumps in isolated fish brain capillaries. Am. J. Physiol.Regul. Integr. Comp. Physiol., 2002, 282(1), R191-198. (Pubitemid 34663926)
23. Pardridge, W. M.; Golden, P. L.; Kang, Y. S.; Bickel, U. Brainmicrovascular and astrocyte localization of P-glycoprotein. J. Neurochem.,1997, 68(3), 1278-1285.
24. Decleves, X.; Regina, A.; Laplanche, J. L.; Roux, F.; Boval, B.;Launay, J. M.; Scherrmann, J. M. Functional expression of Pglycoproteinand multidrug resistance-associated protein (Mrp1) inprimary cultures of rat astrocytes. J. Neurosci. Res., 2000, 60(5),594-601. (Pubitemid 30368275)
25. Yousif, S.; Saubamea, B.; Cisternino, S.; Marie-Claire, C.; Dauchy,S.; Scherrmann, J. M.; Decleves, X. Effect of chronic exposure tomorphine on the rat blood-brain barrier: focus on the Pglycoprotein.J. Neurochem., 2008, 107(3), 647-657.
26. Bendayan, R.; Ronaldson, P. T.; Gingras, D.; Bendayan, M. In situlocalization of P-glycoprotein (ABCB1) in human and rat brain. J.Histochem. Cytochem., 2006, 54(10), 1159-1167. (Pubitemid 44434719)
27. Gazzin, S.; Strazielle, N.; Schmitt, C.; Fevre-Montange, M.; Ostrow,J. D.; Tiribelli, C.; Ghersi-Egea, J. F. Differential expressionof the multidrug resistance-related proteins ABCb1 and ABCc1 betweenblood-brain interfaces. J. Comp. Neurol., 2008, 510(5), 497-507.
28. Doyle, L. A.; Yang, W.; Abruzzo, L. V.; Krogmann, T.; Gao, Y.;Rishi, A. K.; Ross, D. D. A multidrug resistance transporter fromhuman MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. U S A,1998, 95(26), 15665-15670. (Pubitemid 29018757)
29. Ni, Z.; Mark, M. E.; Cai, X.; Mao, Q. Fluorescence resonanceenergy transfer (FRET) analysis demonstrates dimer/oligomer formationof the human breast cancer resistance protein(BCRP/ABCG2) in intact cells. Int. J. Biochem. Mol. Biol., 2010,1(1), 1-11.
30. Fetsch, P. A.; Abati, A.; Litman, T.; Morisaki, K.; Honjo, Y.; Mittal,K.; Bates, S. E. Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues. Cancer Lett., 2006,235(1), 84-92.
31. Maliepaard, M.; Scheffer, G. L.; Faneyte, I. F.; van Gastelen, M.A.; Pijnenborg, A. C.; Schinkel, A. H.; van De Vijver, M. J.;Scheper, R. J.; Schellens, J. H. Subcellular localization and distributionof the breast cancer resistance protein transporter in normalhuman tissues. Cancer Res., 2001, 61(8), 3458-3464. (Pubitemid 32695041)
32. Eisenblatter, T.; Huwel, S.; Galla, H. J. Characterisation of thebrain multidrug resistance protein (BMDP/ABCG2/BCRP) expressedat the blood-brain barrier. Brain Res., 2003, 971(2), 221-231. (Pubitemid 36423323)
33. Cisternino, S.; Mercier, C.; Bourasset, F.; Roux, F.; Scherrmann, J.M. Expression, up-regulation, and transport activity of themultidrug-resistance protein Abcg2 at the mouse blood-brain barrier.Cancer Res., 2004, 64(9), 3296-3301. (Pubitemid 38581436)
34. Lee, G.; Babakhanian, K.; Ramaswamy, M.; Prat, A.; Wosik, K.;Bendayan, R. Expression of the ATP-binding cassette membranetransporter, ABCG2, in human and rodent brain microvessel endothelialand glial cell culture systems. Pharm. Res., 2007, 24(7),1262-1274. (Pubitemid 46870591)
35. Cooray, H. C.; Blackmore, C. G.; Maskell, L.; Barrand, M. A.Localisation of breast cancer resistance protein in microvessel endotheliumof human brain. Neuroreport., 2002, 13(16), 2059-2063. (Pubitemid 36005925)
36. Zhang, W.; Mojsilovic-Petrovic, J.; Andrade, M. F.; Zhang, H.;Ball, M.; Stanimirovic, D. B. The expression and functional characterizationof ABCG2 in brain endothelial cells and vessels. Faseb.J., 2003, 17(14), 2085-2087.
37. Haimeur, A.; Conseil, G.; Deeley, R. G.; Cole, S. P. The MRPrelatedand BCRP/ABCG2 multidrug resistance proteins: biology,substrate specificity and regulation. Curr. Drug Metab., 2004, 5(1),21-53. (Pubitemid 38294344)
38. Deeley, R. G.; Westlake, C.; Cole, S. P. Transmembrane transportof endo- and xenobiotics by mammalian ATP-binding cassettemultidrug resistance proteins. Physiol. Rev., 2006, 86(3), 849-899. (Pubitemid 44033384)
39. Kruh, G. D.; Zeng, H.; Rea, P. A.; Liu, G.; Chen, Z. S.; Lee, K.;Belinsky, M. G. MRP subfamily transporters and resistance to anticanceragents. J. Bioenerg. Biomembr., 2001, 33(6), 493-501. (Pubitemid 34052575)
40. Kusuhara, H.; Suzuki, H.; Naito, M.; Tsuruo, T.; Sugiyama, Y.Characterization of efflux transport of organic anions in a mousebrain capillary endothelial cell line. J. Pharmacol. Exp. Ther.,1998, 285(3), 1260-1265. (Pubitemid 28277927)
41. Regina, A.; Koman, A.; Piciotti, M.; El Hafny, B.; Center, M. S.;Bergmann, R.; Couraud, P. O.; Roux, F. Mrp1 multidrug resistance-associated protein and P-glycoprotein expression in rat brainmicrovessel endothelial cells. J. Neurochem., 1998, 71(2), 705-715. (Pubitemid 28480418)
42. Zhang, Y.; Han, H.; Elmquist, W. F.; Miller, D. W. Expression ofvarious multidrug resistance-associated protein (MRP) homologuesin brain microvessel endothelial cells. Brain Res., 2000, 876(1-2),148-153.
43. Berezowski, V.; Landry, C.; Dehouck, M. P.; Cecchelli, R.; Fenart,L. Contribution of glial cells and pericytes to the mRNA profiles ofP-glycoprotein and multidrug resistance-associated proteins in anin vitro model of the blood-brain barrier. Brain Res., 2004,1018(1), 1-9. (Pubitemid 38942854)
44. Yousif, S.; Marie-Claire, C.; Roux, F.; Scherrmann, J. M.; Decleves,X. Expression of drug transporters at the blood-brain barrierusing an optimized isolated rat brain microvessel strategy. BrainRes., 2007, 1134(1), 1-11. (Pubitemid 46156932)
45. Cisternino, S.; Rousselle, C.; Lorico, A.; Rappa, G.; Scherrmann, J.M. Apparent lack of Mrp1-mediated efflux at the luminal side ofmouse blood-brain barrier endothelial cells. Pharm Res., 2003,20(6), 904-909. (Pubitemid 36628438)
46. Bronger, H.; Konig, J.; Kopplow, K.; Steiner, H. H.; Ahmadi, R.;Herold-Mende, C.; Keppler, D.; Nies, A. T. ABCC drug effluxpumps and organic anion uptake transporters in human gliomas andthe blood-tumor barrier. Cancer Res., 2005, 65(24), 11419-11428. (Pubitemid 41821699)
47. Warren, M. S.; Zerangue, N.; Woodford, K.; Roberts, L. M.; Tate,E. H.; Feng, B.; Li, C.; Feuerstein, T. J.; Gibbs, J.; Smith, B.; deMorais, S. M.; Dower, W. J.; Koller, K. J. Comparative gene expressionprofiles of ABC transporters in brain microvessel endothelialcells and brain in five species including human. Pharmacol.Res., 2009, 59(6), 404-413.
48. Nies, A. T.; Jedlitschky, G.; Konig, J.; Herold-Mende, C.; Steiner,H. H.; Schmitt, H. P.; Keppler, D. Expression and immunolocalizationof the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain. Neuroscience, 2004, 129(2), 349-360. (Pubitemid 39388854)
49. Sugiyama, D.; Kusuhara, H.; Lee, Y. J.; Sugiyama, Y. Involvementof multidrug resistance associated protein 1 (Mrp1) in the effluxtransport of 17beta estradiol-D-17beta-glucuronide (E217betaG)across the blood-brain barrier. Pharm Res., 2003, 20(9), 1394-1400. (Pubitemid 37164047)
50. Miller, D. S.; Nobmann, S. N.; Gutmann, H.; Toeroek, M.; Drewe,J.; Fricker, G. Xenobiotic transport across isolated brain microvesselsstudied by confocal microscopy. Mol. Pharmacol., 2000,58(6), 1357-1367.
51. Hirrlinger, J.; Konig, J.; Dringen, R. Expression of mRNAs ofmultidrug resistance proteins (Mrps) in cultured rat astrocytes, oligodendrocytes, microglial cells and neurones. J. Neurochem., 2002,82(3), 716-719. (Pubitemid 34831509)
52. Zhang, Y.; Schuetz, J. D.; Elmquist, W. F.; Miller, D. W. Plasmamembrane localization of multidrug resistance-associated proteinhomologs in brain capillary endothelial cells. J. Pharmacol. Exp.Ther., 2004, 311(2), 449-455. (Pubitemid 39391528)
53. Leggas, M.; Adachi, M.; Scheffer, G. L.; Sun, D.; Wielinga, P.; Du,G.; Mercer, K. E.; Zhuang, Y.; Panetta, J. C.; Johnston, B.;Scheper, R. J.; Stewart, C. F.; Schuetz, J. D. Mrp4 confers resistanceto topotecan and protects the brain from chemotherapy. Mol.Cell Biol., 2004, 24(17), 7612-7621. (Pubitemid 39121487)
54. Bera, T. K.; Lee, S.; Salvatore, G.; Lee, B.; Pastan, I. MRP8, a newmember of ABC transporter superfamily, identified by EST databasemining and gene prediction program, is highly expressed inbreast cancer. Mol. Med., 2001, 7(8), 509-516.
55. Hopper, E.; Belinsky, M. G.; Zeng, H.; Tosolini, A.; Testa, J. R.;Kruh, G. D. Analysis of the structure and expression pattern ofMRP7 (ABCC10), a new member of the MRP subfamily. CancerLett., 2001, 162(2), 181-191. (Pubitemid 32056287)
56. Chen, C.; Liu, X.; Smith, B. J. Utility of Mdr1-gene deficient micein assessing the impact of P-glycoprotein on pharmacokinetics andpharmacodynamics in drug discovery and development. Curr.Drug Metab., 2003, 4(4), 272-291. (Pubitemid 36958329)
57. Takenaka, K.; Morgan, J. A.; Scheffer, G. L.; Adachi, M.; Stewart,C. F.; Sun, D.; Leggas, M.; Ejendal, K. F.; Hrycyna, C. A.; Schuetz,J. D. Substrate overlap between Mrp4 and Abcg2/Bcrp affectspurine analogue drug cytotoxicity and tissue distribution. CancerRes., 2007, 67(14), 6965-6972. (Pubitemid 47105544)
58. Bihorel, S.; Camenisch, G.; Lemaire, M.; Scherrmann, J. M. Influenceof breast cancer resistance protein (Abcg2) and p-glycoprotein(Abcb1a) on the transport of imatinib mesylate (Gleevec) acrossthe mouse blood-brain barrier. J. Neurochem., 2007, 102(6), 1749-1757. (Pubitemid 47329285)
59. de Vries, N. A.; Zhao, J.; Kroon, E.; Buckle, T.; Beijnen, J. H.; vanTellingen, O. P-glycoprotein and breast cancer resistance protein:two dominant transporters working together in limiting the brainpenetration of topotecan. Clin. Cancer Res., 2007, 13(21), 6440-6449. (Pubitemid 350075034)
60. Kannan, P.; John, C.; Zoghbi, S. S.; Halldin, C.; Gottesman, M. M.;Innis, R. B.; Hall, M. D. Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin.Pharmacol. Ther., 2009, 86(4), 368-377.
61. Muzi, M.; Mankoff, D. A.; Link, J. M.; Shoner, S.; Collier, A. C.;Sasongko, L.; Unadkat, J. D. Imaging of cyclosporine inhibition ofP-glycoprotein activity using 11C-verapamil in the brain: studies ofhealthy humans. J. Nucl. Med., 2009, 50(8), 1267-1275.
62. Seneca, N.; Zoghbi, S. S.; Liow, J. S.; Kreisl, W.; Herscovitch, P.;Jenko, K.; Gladding, R. L.; Taku, A.; Pike, V. W.; Innis, R. B.Human brain imaging and radiation dosimetry of 11C-Ndesmethyl-loperamide, a PET radiotracer to measure the functionof P-glycoprotein. J. Nucl. Med., 2009, 50(5), 807-813.
63. Mairinger, S.; Langer, O.; Kuntner, C.; Wanek, T.; Bankstahl, J. P.;Bankstahl, M.; Stanek, J.; Dorner, B.; Bauer, F.; Baumgartner, C.;Loscher, W.; Erker, T.; Muller, M. Synthesis and in vivo evaluationof the putative breast cancer resistance protein inhibitor[11C]methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4- tetrahydroisoquinolin-2-yl)ethyl)phenyl)am ino-carbonyl)-2-(quinoline-2- carbonylamino)benzoate. Nucl. Med. Biol., 2010, 37(5), 637-644.
64. Bertler, A.; Falck, B.; Owman, C.; Rosengrenn, E. The localizationof monoaminergic blood-brain barrier mechanisms. Pharmacol.Rev., 1966, 18(1), 369-385.
65. Owman, C.; Rosengren, E. Dopamine formation in brain capillaries - an enzymic blood-brain barrier mechanism. J. Neurochem.,1967, 14(5), 547-550.
66. el-Bacha, R. S.; Minn, A. Drug metabolizing enzymes in cerebrovascularendothelial cells afford a metabolic protection to thebrain. Cell Mol. Biol. (Noisy-le-grand), 1999, 45(1), 15-23.
67. Walther, B.; Ghersi-Egea, J. F.; Minn, A.; Siest, G. Subcellulardistribution of cytochrome P-450 in the brain. Brain Res., 1986,375(2), 338-344.
68. Strobel, H. W.; Thompson, C. M.; Antonovic, L. CytochromesP450 in brain: function and significance. Curr. Drug Metab., 2001,2(2), 199-214.
69. Ghersi-Egea, J. F.; Leninger-Muller, B.; Suleman, G.; Siest, G.;Minn, A. Localization of drug-metabolizing enzyme activities toblood-brain interfaces and circumventricular organs. J. Neurochem.,1994, 62(3), 1089-1096. (Pubitemid 24064523)
70. Ghersi-Egea, J. F.; Minn, A.; Siest, G. A new aspect of the protectivefunctions of the blood-brain barrier: activities of four drugmetabolizingenzymes in isolated rat brain microvessels. Life Sci.,1988, 42(24), 2515-2523.
71. Chen, Z. R.; Irvine, R. J.; Bochner, F.; Somogyi, A. A. Morphineformation from codeine in rat brain: a possible mechanism of codeineanalgesia. Life Sci., 1990, 46(15), 1067-1074. (Pubitemid 20148780)
72. Hansson, T.; Tindberg, N.; Ingelman-Sundberg, M.; Kohler, C.Regional distribution of ethanol-inducible cytochrome P450 IIE1 inthe rat central nervous system. Neuroscience, 1990, 34(2), 451-463. (Pubitemid 20110150)
73. Chat, M.; Bayol-Denizot, C.; Suleman, G.; Roux, F.; Minn, A.Drug metabolizing enzyme activities and superoxide formation inprimary and immortalized rat brain endothelial cells. Life Sci.,1998, 62(2), 151-163. (Pubitemid 28026747)
74. Granberg, L.; Ostergren, A.; Brandt, I.; Brittebo, E. B. CYP1A1and CYP1B1 in blood-brain interfaces: CYP1A1-dependent bioactivationof 7,12-dimethylbenz(a)anthracene in endothelial cells.Drug Metab. Dispos., 2003, 31(3), 259-265. (Pubitemid 36249679)
75. Morse, D. C.; Stein, A. P.; Thomas, P. E.; Lowndes, H. E. Distributionand induction of cytochrome P450 1A1 and 1A2 in rat brain.Toxicol. Appl. Pharmacol., 1998, 152(1), 232-239. (Pubitemid 28498691)
76. Filbrandt, C. R.; Wu, Z.; Zlokovic, B.; Opanashuk, L.; Gasiewicz,T. A. Presence and functional activity of the aryl hydrocarbon receptorin isolated murine cerebral vascular endothelial cells and astrocytes.Neurotoxicology, 2004, 25(4), 605-616. (Pubitemid 38739117)
77. Dutheil, F.; Beaune, P.; Loriot, M. A. Xenobiotic metabolizingenzymes in the central nervous system: Contribution of cytochromeP450 enzymes in normal and pathological human brain. Biochimie,2008, 90(3), 426-436.
78. Dutheil, F.; Jacob, A.; Dauchy, S.; Beaune, P.; Scherrmann, J. M.;Decleves, X.; Loriot, M. A. ABC transporters and cytochromesP450 in the human central nervous system: influence on brainpharmacokinetics and contribution to neurodegenerative disorders.Expert Opin. Drug Metab. Toxicol., 2010, 6(10), 1161-1174.
79. Vasiliou, V.; Gonzalez, F. J. Role of CYP1B1 in glaucoma. Annu.Rev. Pharmacol. Toxicol., 2008, 48, 333-358. (Pubitemid 351738157)
80. Xu, C.; Li, C. Y.; Kong, A. N. Induction of phase I, II and III drugmetabolism/transport by xenobiotics. Arch. Pharm. Res., 2005,28(3), 249-268. (Pubitemid 44698742)
81. Zastre, J. A.; Chan, G. N.; Ronaldson, P. T.; Ramaswamy, M.;Couraud, P. O.; Romero, I. A.; Weksler, B.; Bendayan, M.; Bendayan,R. Up-regulation of P-glycoprotein by HIV protease inhibitorsin a human brain microvessel endothelial cell line. J. Neurosci.Res., 2009, 87(4), 1023-1036.
82. Dauchy, S.; Miller, F.; Couraud, P. O.; Weaver, R. J.; Weksler, B.;Romero, I. A.; Scherrmann, J. M.; De Waziers, I.; Decleves, X.Expression and transcriptional regulation of ABC transporters andcytochromes P450 in hCMEC/D3 human cerebral microvascularendothelial cells. Biochem. Pharmacol., 2009, 77(5), 897-909.
83. Akanuma, S.; Hori, S.; Ohtsuki, S.; Fujiyoshi, M.; Terasaki, T.Expression of nuclear receptor mRNA and liver X receptormediatedregulation of ABC transporter A1 at rat blood-brain barrier.Neurochem. Int., 2008, 52(4-5), 669-674.
84. Bauer, B.; Hartz, A. M.; Fricker, G.; Miller, D. S. Pregnane Xreceptor up-regulation of P-glycoprotein expression and transportfunction at the blood-brain barrier. Mol. Pharmacol., 2004, 66(3),413-419. (Pubitemid 39329239)
85. Bauer, B.; Yang, X.; Hartz, A. M.; Olson, E. R.; Zhao, R.; Kalvass,J. C.; Pollack, G. M.; Miller, D. S. In vivo activation of humanpregnane X receptor tightens the blood-brain barrier to methadonethrough P-glycoprotein up-regulation. Mol. Pharmacol., 2006,70(4), 1212-1219. (Pubitemid 44435972)
86. Ott, M.; Fricker, G.; Bauer, B. Pregnane X receptor (PXR) regulatesP-glycoprotein at the blood-brain barrier: functional similaritiesbetween pig and human PXR. J. Pharmacol. Exp. Ther., 2009,329(1), 141-149.
87. Wang, X.; Sykes, D. B.; Miller, D. S. Constitutive androstane receptor-mediated up-regulation of ATP-driven xenobiotic effluxtransporters at the blood-brain barrier. Mol. Pharmacol., 78(3),376-383.
88. Bieche, I.; Narjoz, C.; Asselah, T.; Vacher, S.; Marcellin, P.; Lidereau,R.; Beaune, P.; de Waziers, I. Reverse transcriptase-PCRquantification of mRNA levels from cytochrome (CYP)1, CYP2and CYP3 families in 22 different human tissues. Pharmacogenet.Genomics, 2007, 17(9), 731-742. (Pubitemid 47263068)
89. Kawakami, H.; Ohtsuki, S.; Kamiie, J.; Suzuki, T.; Abe, T.;Terasaki, T. Simultaneous absolute quantification of 11 cytochromeP450 isoforms in human liver microsomes by liquid chromatographytandem mass spectrometry with In silico target peptideselection. J. Pharm. Sci., 2010.
90. Giacomini, K. M.; Huang, S. M.; Tweedie, D. J.; Benet, L. Z.;Brouwer, K. L.; Chu, X.; Dahlin, A.; Evers, R.; Fischer, V.; Hillgren,K. M.; Hoffmaster, K. A.; Ishikawa, T.; Keppler, D.; Kim, R.B.; Lee, C. A.; Niemi, M.; Polli, J. W.; Sugiyama, Y.; Swaan, P.W.; Ware, J. A.; Wright, S. H.; Yee, S. W.; Zamek-Gliszczynski,M. J.; Zhang, L. Membrane transporters in drug development. Nat.Rev. Drug Discov., 2010, 9(3), 215-236.
91. Ebert, B.; Seidel, A.; Lampen, A. Identification of BCRP as transporterof benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists. Carcinogenesis,2005, 26(10), 1754-1763. (Pubitemid 41487991)
92. Jigorel, E.; Le Vee, M.; Boursier-Neyret, C.; Parmentier, Y.;Fardel, O. Differential regulation of sinusoidal and canalicular hepaticdrug transporter expression by xenobiotics activating drugsensingreceptors in primary human hepatocytes. Drug Metab. Dispos.,2006, 34(10), 1756-1763. (Pubitemid 44427479)
93. Tan, K. P.; Wang, B.; Yang, M.; Boutros, P. C.; Macaulay, J.; Xu,H.; Chuang, A. I.; Kosuge, K.; Yamamoto, M.; Takahashi, S.; Wu,A. M.; Ross, D. D.; Harper, P. A.; Ito, S. Aryl hydrocarbon receptoris a transcriptional activator of the human breast cancer resistanceprotein (BCRP/ABCG2). Mol. Pharmacol., 2010, 78(2), 175-185.
94. Tompkins, L. M.; Li, H.; Li, L.; Lynch, C.; Xie, Y.; Nakanishi, T.;Ross, D. D.; Wang, H. A novel xenobiotic responsive elementregulated by aryl hydrocarbon receptor is involved in the inductionof BCRP/ABCG2 in LS174T cells. Biochem. Pharmacol., 2010,80(11), 1754-1761.
95. Ebert, B.; Seidel, A.; Lampen, A. Phytochemicals induce breastcancer resistance protein in Caco-2 cells and enhance the transportof benzo[a]pyrene-3-sulfate. Toxicol. Sci., 2007, 96(2), 227-236. (Pubitemid 46436705)
96. Conney, A. H. Induction of microsomal enzymes by foreignchemicals and carcinogenesis by polycyclic aromatic hydrocarbons:G. H. A. Clowes Memorial Lecture. Cancer Res., 1982,42(12), 4875-4917. (Pubitemid 13223122)
97. Shimada, T.; Fujii-Kuriyama, Y. Metabolic activation of polycyclicaromatic hydrocarbons to carcinogens by cytochromes P450 1A1and 1B1. Cancer Sci., 2004, 95(1), 1-6. (Pubitemid 38208399)
98. Krusekopf, S.; Roots, I.; Hildebrandt, A. G.; Kleeberg, U. Timedependenttranscriptional induction of CYP1A1, CYP1A2 andCYP1B1 mRNAs by H+/K+ -ATPase inhibitors and other xenobiotics.Xenobiotica, 2003, 33(2), 107-118. (Pubitemid 36237934)
99. Adkison, K. K.; Vaidya, S. S.; Lee, D. Y.; Koo, S. H.; Li, L.; Mehta,A. A.; Gross, A. S.; Polli, J. W.; Humphreys, J. E.; Lou, Y.;Lee, E. J. Oral sulfasalazine as a clinical BCRP probe substrate:pharmacokinetic effects of genetic variation (C421A) and pantoprazolecoadministration. J. Pharm. Sci., 2010, 99(2), 1046-1062.
100. Breedveld, P.; Pluim, D.; Cipriani, G.; Wielinga, P.; van Tellingen,O.; Schinkel, A. H.; Schellens, J. H. The effect of Bcrp1 (Abcg2)on the in vivo pharmacokinetics and brain penetration of imatinibmesylate (Gleevec): implications for the use of breast cancer resistanceprotein and P-glycoprotein inhibitors to enable the brainpenetration of imatinib in patients. Cancer Res., 2005, 65(7), 2577-2582. (Pubitemid 40490054)
101. Dutheil, F.; Dauchy, S.; Diry, M.; Sazdovitch, V.; Cloarec, O.;Mellottee, L.; Bieche, I.; Ingelman-Sundberg, M.; Flinois, J. P.; deWaziers, I.; Beaune, P.; Decleves, X.; Duyckaerts, C.; Loriot, M.A. Xenobiotic-metabolizing enzymes and transporters in the normalhuman brain: regional and cellular mapping as a basis for putativeroles in cerebral function. Drug Metab. Dispos., 2009, 37(7),1528-1538.
102. Hilgendorf, C.; Ahlin, G.; Seithel, A.; Artursson, P.; Ungell, A. L.;Karlsson, J. Expression of thirty-six drug transporter genes in humanintestine, liver, kidney, and organotypic cell lines. Drug Metab.Dispos., 2007, 35(8), 1333-1340. (Pubitemid 47121774)
103. Polli, J. W.; Olson, K. L.; Chism, J. P.; John-Williams, L. S.; Yeager,R. L.; Woodard, S. M.; Otto, V.; Castellino, S.; Demby, V. E.An unexpected synergist role of P-glycoprotein and breast cancerresistance protein on the central nervous system penetration of thetyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl] amino}methyl)-2-furyl]-4-quinazolinamine; GW572016). Drug Metab. Dispos.,2009, 37(2), 439-442.
104. Kodaira, H.; Kusuhara, H.; Ushiki, J.; Fuse, E.; Sugiyama, Y. Kineticanalysis of the cooperation of P-glycoprotein (P-gp/Abcb1)and breast cancer resistance protein (Bcrp/Abcg2) in limiting thebrain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.J. Pharmacol. Exp. Ther., 2010, 333(3), 788-796.
105. Chen, Y.; Agarwal, S.; Shaik, N. M.; Chen, C.; Yang, Z.; Elmquist,W. F. P-glycoprotein and breast cancer resistance protein influencebrain distribution of dasatinib. J. Pharmacol. Exp. Ther., 2009,330(3), 956-963.
106. Zhou, L.; Schmidt, K.; Nelson, F. R.; Zelesky, V.; Troutman, M.D.; Feng, B. The effect of breast cancer resistance protein and Pglycoproteinon the brain penetration of flavopiridol, imatinib mesylate(Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) inmice. Drug Metab. Dispos., 2009, 37(5), 946-955.
107. Agarwal, S.; Sane, R.; Gallardo, J. L.; Ohlfest, J. R.; Elmquist, W.F. Distribution of gefitinib to the brain is limited by P-glycoprotein(ABCB1) and breast cancer resistance protein (ABCG2)-mediatedactive efflux. J. Pharmacol. Exp. Ther., 2010, 334(1), 147-155.